Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 6/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.42 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18389996 | 0.86 | HSD11B1 (0.45) | HSD11B1SMN1; SMN2CACNA2D1CACNA1BCACNB1 | |
| SCHEMBL4470728 | 0.86 | CACNA2D1 (0.51) | SMN1; SMN2CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL3555476 | 0.83 | CHRM5 (0.54) | SMN1; SMN2MAPTGAATHRB | |
| SCHEMBL4321783 | 0.83 | CHRM5 (0.48) | SMN1; SMN2MAPTGAATHRB | |
| SCHEMBL3825062 | 0.83 | SMN1; SMN2 (0.44) | SMN1; SMN2CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL27571743 | 0.82 | CACNA2D1 (0.58) | SMN1; SMN2CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL3165975 | 0.81 | CHRM5 (0.57) | SMN1; SMN2MAPTGAATHRB | |
| SCHEMBL22520730 | 0.81 | HSD11B1 (0.41) | HSD11B1SMN1; SMN2CACNA2D1CACNA1BCACNB1 | |
| SCHEMBL2748651 | 0.80 | KDM4E (0.53) | HSD11B1KDM4E | |
| SCHEMBL22520700 | 0.80 | ACHE (0.50) | HSD11B1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538111-B2 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LABORATOIRES FOURNIER S.A. (FR) | 2009-05-26 | — | — | US | disclosed |
| US-20060178360-A1 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LABORATOIRES FOURNIER S.A. (FR) | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178360-A1 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LTB4R2, BDKRB2, TBXA2R | HSD11B1 699/4885SMN1; SMN2 1897/4885CACNA2D1 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.